- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
April 29, 2024Robins Kaplan Mourns Death of New York Associate Waleed Abbasi
-
April 29, 2024Robins Kaplan Secures $7.75 Million Verdict in Aerosol Dust Remover Abuse Case
-
April 23, 2024David Martinez Recognized Among Top 100 Lawyers in Los Angeles by LA Business Journal
-
May 20, 2024The Present and Future of DEI
-
May 23, 202414th Annual Disability Justice Seminar
-
June 10-11, 20242024 Probate and Trust Law Section Conference
-
April 30, 2024A World Without Non-Competes: Protecting Confidential Information and Trade Secrets Following the FTC's Ban
-
First QuarterGENERICally Speaking: A Hatch-Waxman Litigation Bulletin
-
March 2024e-Commerce: Pitfalls and Protections
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
New ANDA Cases
Federal district court cases that are filed pursuant to the Hatch-Waxman Act
Second Quarter
This New ANDA Cases chart summarizes the case name, presiding judge, drug, and patents-at-issue in all federal district court cases that are filed pursuant to the Hatch-Waxman Act. It also includes the same information for proceedings before the Patent Trial and Appeal Board concerning Orange Book-listed patents.
| Case Name | Date Filed | Judge | Drug | Patent No(s). |
|---|---|---|---|---|
| AbbVie Inc. v. Teva Pharms., Inc., 24-0374 (D. Del.) | Apr. 3, 2023 | Hon. Richard G. Andrews | Orilissa® (elagolix sodium tablets) | 11,542,239 |
| Ingenus Pharms., LLC v. Accord Healthcare, Inc., 23-0377 (D. Del.) | Apr. 3, 2023 | Hon. Colm F. Connolly | Cyclophosphamide intravenous solution | 10,993,952 |
| Actelion Pharms. US, Inc. v. Alembic Pharms. Ltd., 23-0383 (D. Del.) | Apr. 4, 2023 | Hon. Gregory B. Williams | Uptravi® (selexipag tablets) | 7,205,302 |
| Actelion Pharms. US, Inc. v. Alembic Pharms. Ltd., 23-1902 (D.N.J.) | Apr. 4, 2023 | Hon. Stanley R. Chesler | Opsumit® (macitentan tablets) | 7,094,781 |
| Catalyst Pharms., Inc. v. MSN Labs. Private Ltd., 23-1945 (D.N.J.) | Apr. 5, 2023 | Hon. Karen M. Williams | Fycompa® (perampanel oral suspension) | 8,722,497 |
| Actelion Pharms. US, Inc. v. Cipla Ltd., 23-0389 (D. Del.) | Apr. 6, 2023 | Hon. Gregory B. Williams | Uptravi® (selexipag for injection) | 8,791,122 9,284,280 |
| Bristol-Myers Squibb Co. v. Biocon Pharma Ltd., 23-0392 (D. Del.) | Apr. 6, 2023 | Hon. Gregory B. Williams | Eliquis® (apixaban tablets) | 9,326,945 |
| Bristol-Myers Squibb Co. v. ScieGen Pharms., Inc., 23-0393 (D. Del.) | Apr. 6, 2023 | Hon. Gregory B. Williams | Eliquis® (apixaban tablets) | 9,326,945 |
| Catalyst Pharms., Inc. v. MSN Labs. Private Ltd., 23-1961 (D.N.J.) | Apr. 6, 2023 | Hon. Karen M. Williams | Fycompa® (perampanel tablets) | 8,722,497 |
| Abraxis Bioscience, LLC v. Mylan Pharms. Inc., 23-0033 (N.D.W.V.) | Apr. 6, 2023 | Hon. Thomas S Kleeh | Abraxane® (paclitaxel protein-bound particles for injectable suspension) | 7,820,788 |
| Novartis Pharms. Corp. v. Nanjing Noratech Pharm. Co., Ltd., 23-0401 (D. Del.) | Apr. 10, 2023 | Hon. Richard G. Andrews | Entresto® (sacubitril / valsartan tablets) | 8,101,659 11,058,667 |
| Nexus Pharms., Inc. v. Gland Pharma Ltd., 23-2032 (D.N.J.) | Apr. 10, 2023 | Hon. Christine P. O’Hearn | Emerphed® (ephedrine sulfate injection) | 11,090,278 11,241,400 11,478,436 11,426,369 |
| Bayer Pharma AG v. Dr. Reddy’s Labs., Inc., 23-0410 (D. Del.) | Apr. 13, 2023 | Hon. Richard G. Andrews | Xarelto® (rivaroxaban tablets) | 10,828,310 |
| Celgene Corp. v. Accord Healthcare Inc., 23-0424 (D. Del.) | Apr. 18, 2023 | Hon. Richard G. Andrews | Onureg® (azacitidine tablets) | 11,571,436 |
| Pfizer Inc. v. Apotex Inc., 23-0445 (D. Del.) | Apr. 24, 2023 | Hon. Colm F. Connolly | Xeljanz® (tofacitinib) tablets | RE41,783 |
| AbbVie Inc. v. Hetero Labs Ltd., 23-0448 (D. Del.) | Apr. 24, 2023 | Hon. Richard G. Andrews | Orilissa® (elagolix sodium tablets) | 11,542,239 |
| AbbVie Inc. v. Prinston Pharm. Inc., 23-0470 (D. Del.) | Apr. 28, 2023 | Hon. Richard G. Andrews | Orilissa® (elagolix sodium tablets) | 10,537,572 10,682,351 |
| Merck Sharp & Dohme LLC v. Hetero USA Inc., 23-2364 (D.N.J.) | Apr. 28, 2023 | Hon. Claire C. Cecchi | Isentress® (raltegravir tablets) | 7,754,731 |
| Pacira Pharms., Inc. v. eVenus Pharms. Labs. Inc., 23-2367 (D.N.J.) | Apr. 28, 2023 | Hon Madeline Cox Arleo | Exparel® (bupivacaine liposome injectable suspension) | 11,033,495 |
| Astellas Pharma Inc. v. Ascent Pharms., Inc., 23-0486 (D. Del.) | 3-May-23 | Hon. Joseph F. Bataillon | Myrbetriq® (mirabegron extended-release tablets) | 10,842,780 |
| Bausch & Lomb, Inc. v. Lupin Ltd., 23-2452 (D.N.J.) | 3-May-23 | Hon. Georgette Castner | Lumify® (brimonidine tartrate ophthalmic solution) | 11,596,600 |
| Bausch & Lomb, Inc. v. Slayback Pharma LLC, 23-2454 (D.N.J.) | 3-May-23 | Hon. Georgette Castner | Lumify® (brimonidine tartrate ophthalmic solution) | 11,596,600 |
| Teva Pharms. Int’l GmbH v. BendaRx Corp., 23-0490 (D. Del.) | 4-May-23 | Hon. Colm F. Connolly | Treanda® (bendamustine HCl for injection) Bendeka® (bendamustine HCl for injection) | 8,436,190 8,445,524 8,609,863 8,669,279 8,791,270 8,883,836 8,895,756 9,533,955 9,572,887 8,076,366 8,461,350 |
| Astellas Pharma Inc. v. Ascent Pharms., Inc., 23-3372 (E.D.N.Y.) | 4-May-23 | Hon. Joan M. Azrack | Myrbetriq® (mirabegron extended-release tablets) | 10,842,780 |
| Gilead Sciences, Inc. v. Lupin Ltd., 23-0508 (D. Del.) | 9-May-23 | Hon. Maryellen Noreika | Symtuza® (darunavir / cobicistat / emtricitabine / tenofovir alafenamide tablets) | 10,039,718 10,786,518 |
| Bausch & Lomb Inc. v. Lupin Ltd., 23-2664 (D.N.J.) | 17-May-23 | Hon. Julien Xavier Neals | Lotemax® SM (loteprednol etabonate ophthalmic gel) | 11,534,395 |
| Bausch Health Ireland Ltd. v. Taro Pharms. Inc., 23-2684 (D.N.J.) | 17-May-23 | Hon. Stanley R. Chesler | Duobrii® (halobetasol propionate / tazarotene lotion) | 11,648,256 |
| Acerta Pharma BV v. Alembic Pharms. Ltd., 23-0548 (D. Del.) | 19-May-23 | Hon. Gregory B. Williams | Calquence® (acalabrutinib capsules) | 10,272,083 |
| Novartis Pharms. Corp. v. MSN Pharms. Inc., 23-0550 (D. Del.) | 19-May-23 | Hon. Gregory B. Williams | Kisqali® (ribociclib tablets) Kisqali® Femara® Co-Pack (ribociclib / letrozole tablets) | 8,962,630 9,416,136 |
| Bayer Pharma AG v. Teva Pharms. USA, Inc., 23-0551 (D. Del.) | 19-May-23 | Hon. Richard G. Andrews | Xarelto® (rivaroxaban tablets) | 10,828,310 |
| Nexus Pharms., Inc. v. Exela Pharma Sciences, LLC, 23-0555 (D. Del.) | 19-May-23 | Hon. Maryellen Noreika | Akovaz® (ephedrine sulfate solution for injection) Emerphed® (ephedrine sulfate solution for injection) | 11,571,398 |
| Mylan Pharms. Inc. v. Bayer Intellectual Property GmbH, 23-0556 (D. Del.) | 19-May-23 | Hon. Richard G. Andrews | Xarelto® (rivaroxaban tablets) | 9,415,053 |
| Theravance Biopharma R&D IP, LLC v . Orbicular Pharm. Technologies Private Ltd., 23-2843 (D.N.J.) | 24-May-23 | Hon. Karen M. Williams | Yupelri® (revefenacin inhalation solution) | 11,484,531 |
| Braintree Labs., Inc. v. Lupin Ltd., 23-2853 (D.N.J.) | 25-May-23 | Hon. Christine P. O’Hearn | Sutab® (sodium sulfate / magnesium sulfate / potassium chloride osmotic laxative tablets) | 10,143,656 11,033,498 11,382,864 |
| Vertex Pharms. Inc. v. Lupin Ltd., 23-0581 (D. Del.) | 26-May-23 | Hon. Richard G. Andrews | Kalydeco® (ivacaftor tablets) | 10,646,481 11,564,916 |
| Vertex Pharms. Inc. v. Aurobindo Pharma Ltd., 23-0582 (D. Del.) | 26-May-23 | Hon. Richard G. Andrews | Kalydeco® (ivacaftor tablets) | 10,646,481 11,564,916 |
| Vertex Pharms. Inc. v. Lupin Ltd., 23-0583 (D. Del.) | 26-May-23 | Hon. Richard G. Andrews | Kalydeco® (ivacaftor tablets) | 8,883,206 10,272,046 10,646,481 11,147,770 11,564,916 |
| Janssen Pharms., Inc. v. Alkem Labs. Ltd., 23-2939 (D.N.J.) | 30-May-23 | Hon. Karen M. Williams | Spravato® (esketamine nasal spray) | 10,869,844 11,173,134 11,311,500 11,446,260 |
| Janssen Pharms., Inc. v. Hikma Pharms. USA Inc., 23-2942 (D.N.J.) | 30-May-23 | Hon. Karen M. Williams | Spravato® (esketamine nasal spray) | 10,869,844 11,173,134 11,311,500 11,446,260 |
| Janssen Pharms., Inc. v. Sandoz Inc., 23-2943 (D.N.J.) | 30-May-23 | Hon. Karen M. Williams | Spravato® (esketamine nasal spray) | 10,869,844 11,173,134 11,311,500 11,446,260 |
| Janssen Pharms., Inc. v. Hikma Pharms. USA Inc., 23-0595 (D. Del.) | 31-May-23 | Hon. Colm F. Connolly | Spravato® (esketamine nasal spray) | 10,869,844 11,173,134 11,311,500 11,446,260 |
| Janssen Pharms., Inc. v. Sandoz Inc., 23-0597 (D. Del.) | 31-May-23 | Hon. Colm F. Connolly | Spravato® (esketamine nasal spray) | 10,869,844 11,173,134 11,311,500 11,446,260 |
| Celgene Corp. v. Deva Holding A.S., 23-2992 (D.N.J.) | 31-May-23 | Hon. Susan D. Wigenton | Revlimid® (lenalidomide capsules) | 7,465,800 7,855,217 |
| Evofem Biosciences, Inc. v. Padagis Israel Pharms. Ltd., 23-3003 (D.N.J.) | 1-Jun-23 | Hon. Zahid N. Quaraishi | Phexxi® (lactic acid / citric acid / potassium bitartrate vaginal gel) | 10,568,855 11,337,989 11,439,610 |
| Bayer Intellectual Property GmbH v. Auson Pharms. Inc., 23-3020 (D.N.J.) | 1-Jun-23 | Hon. Evelyn Padin | Xarelto® (rivaroxaban tablets) | 9,539,218 10,828,310 |
| Evofem Biosciences, Inc. v. Padagis Israel Pharms. Ltd., 23-0606 (D. Del.) | 2-Jun-23 | Hon. Colm F. Connolly | Phexxi® (lactic acid / citric acid / potassium bitartrate vaginal gel) | 10,568,855 11,337,989 11,439,610 |
| AbbVie Inc. v. Prinston Pharm. Inc., 23-0607 (D. Del.) | 2-Jun-23 | Hon. Richard G. Andrews | Orilissa® (elagolix sodium tablets) | 11,542,239 |
| Horizon Therapeutics USA Inc. v. Dr. Reddy’s Labs., Ltd., 23-0623 (D. Del.) | 7-Jun-23 | Hon. Maryellen Noreika | Rayos® (prednisone delayed-release tablets) | 9,504,699 |
| Array BioPharma Inc. v. Teva Pharms., Inc., 23-0625 (D. Del.) | 8-Jun-23 | Hon. Gregory B. Williams | Mektovi® (binimetinib tablets) | 9,562,016 9,598,376 9,980,944 |
| Teva Pharms. Int’l GmbH v. BendaRx Corp., 23-0633 (D. Del.) | 9-Jun-23 | Hon. Colm F. Connolly | Treanda® (bendamustine HCl for injection) Bendeka® (bendamustine HCl for injection) | 8,436,190 8,445,524 8,609,863 8,669,279 8,791,270 8,883,836 8,895,756 9,533,955 9,572,887 8,076,366 8,461,350 |
| Pfizer Inc. v. Annora Pharma Private Ltd., 23-0634 (D. Del.) | 9-Jun-23 | Hon. Colm F. Connolly | Xeljanz® (tofacitinib oral solution) | RE41,783 |
| Jazz Pharms. Ireland Ltd. v. Alkem Labs. Ltd., 23-3182 (D.N.J.) | 9-Jun-23 | Hon. Stanley R. Chesler | Xyrem® (sodium oxybate oral solution) | 8,772,306 9,050,302 9,486,426 10,213,400 10,864,181 11,253,494 |
| Hikma Pharms. USA Inc. v. Padagis Israel Pharms. Ltd., 23-0654 (D. Del.) | 14-Jun-23 | Hon. Gregory B. Williams | Kloxxado® (naloxone HCl nasal spray) | 10,722,510 10,973,814 11,135,155 11,617,713 11,628,139 |
| Merck KGaA v. Apotex Inc., 23-0655 (D. Del.) | 15-Jun-23 | Hon. Gregory B. Williams | Mavenclad® (cladribine tablets) | 7,713,947 8,377,903 10,849,919 |
| Bayer Pharma AG v. Macleods Pharms. Ltd., 23-0665 (D. Del.) | 16-Jun-23 | Hon. Richard G. Andrews | Xarelto® (rivaroxaban tablets) | 10,828,310 |
| Vertex Pharms. Inc. v. Sun Pharm. Indus. Ltd., 23-0666 (D. Del.) | 16-Jun-23 | Hon. Richard G. Andrews | Kalydeco® (ivacaftor tablets) | 10,646,481 11,564,916 |
| Hikma Pharms. USA Inc. v. Padagis Israel Pharms. Ltd., 23-0630 (W.D. Mich.) | 16-Jun-23 | Hon. Paul L. Maloney | Kloxxado® (naloxone HCl nasal spray) | 10,722,510 10,973,814 11,135,155 11,617,713 11,628,139 |
| Bausch Health Ireland Ltd. v. MSN Labs. Private Ltd., 23-3333 (D.N.J.) | 16-Jun-23 | Hon. Stanley R. Chesler | Trulance® (plecanatide tablets) | 11,142,549 11,319,346 |
| Teva Pharms. Int’l GmbH v. BendaRx USA Corp., 23-0788 (E.D. Va.) | 16-Jun-23 | Hon. Rossie D. Alston, Jr. | Treanda® (bendamustine HCl for injection) Bendeka® (bendamustine HCl for injection) | 8,436,190 8,445,524 8,609,863 8,669,279 8,791,270 8,883,836 8,895,756 9,533,955 9,572,887 8,076,366 8,461,350 |
| Actelion Pharms. Ltd. v. MSN Labs. Private Ltd., 23-3371 (D.N.J.) | 20-Jun-23 | Hon. Stanley R. Chesler | Opsumit® (macitentan tablets) | 7,094,781 |
| Bausch Health Ireland Ltd. v. Padagis Israel Pharms. Ltd., 23-3393 (D.N.J.) | 21-Jun-23 | Hon. Stanley R. Chesler | Arazlo® (tazarotene lotion) | 11,679,116 |
| Padagis Israel Pharms. Ltd. v. Bausch Health US, LLC, IPR2023-01114 (PTAB) | 21-Jun-23 | N/A | Arazlo® (tazarotene lotion) | 11,311,482 |
| Merck Sharp & Dohme LLC v. Biocon Pharma Ltd., 23-0683 (D. Del.) | 23-Jun-23 | Hon. Richard G. Andrews | Januvia® (sitagliptin phosphate tablets) | 7,326,708 |
| AbbVie Inc. v. Sun Pharm. Indus. Ltd., 23-0684 (D. Del.) | 23-Jun-23 | Hon. Richard G. Andrews | Orilissa® (elagolix sodium tablets) | 11,542,239 |
| Boehringer Ingelheim Pharms. Inc. v. Apotex Inc., 23-0685 (D. Del.) | 23-Jun-23 | Hon. Colm F. Connolly | Tradjenta® (linagliptin tablets) | 9,486,526 10,034,877 |
| Astellas Pharma Inc. v. MSN Pharms. Inc., 23-0689 (D. Del.) | 23-Jun-23 | Hon. Joseph F. Bataillon | Myrbetriq® (mirabegron extended-release tablets) | 10,842,780 |
| Bayer Intellectual Property GmbH v. Indoco Remedies Ltd., 23-0690 (D. Del.) | 23-Jun-23 | Hon. Richard G. Andrews | Xarelto® (rivaroxaban tablets) | 9,539,218 10,828,310 |
| Celgene Corp. v. MSN Labs. Private Ltd., 23-0699 (D. Del.) | 27-Jun-23 | Hon. Richard G. Andrews | Onureg® (azacitidine tablets) | 8,846,628 11,571,436 |
| Bausch & Lomb Inc. v. Dr. Reddy’s Labs. Ltd., 23-3463 (D.N.J.) | 27-Jun-23 | Hon. Robert Kirsch | Vyzulta® (latanoprostene bunod ophthalmic solution) | 7,273,946 7,629,345 7,910,767 8,058,467 |
| Amring Pharms. Inc. v. Rubicon Research Private Ltd., 23-3494 (D.N.J.) | 28-Jun-23 | Hon. Susan D. Wigenton | Lysteda® (tranexamic acid tablets) | 7,947,739 8,022,106 8,273,795 8,487,005 8,791,160 8,809,394 8,957,113 9,060,939 |
| Boehringer Ingelheim Pharms., Inc. v. Anobri Pharms. US, LLC, 23-3530 (D.N.J.) | 29-Jun-23 | Hon. Claire C. Cecchi | Spiriva® Respimat® (tiotropium bromide inhalation spray) | 7,284,474 7,896,264 7,396,341 9,027,967 7,837,235 8,733,341 |
| Boehringer Ingelheim Pharms., Inc. v. Anobri Pharms. US, LLC, 23-3531 (D.N.J.) | 29-Jun-23 | Hon. Claire C. Cecchi | Combivent® Respimat® (ipratropium bromide / albuterol inhalation spray) | 7,284,474 7,896,264 7,396,341 9,027,967 7,837,235 8,733,341 |
| Otsuka Pharm. Co., Ltd. v. Apotex Inc., 23-0710 (D. Del.) | 30-Jun-23 | Hon. Richard G. Andrews | Jynarque® (tolvaptan tablets) | 8,501,730 8,273,735 |
| Galderma Labs., L.P. v. Dr. Reddy’s Labs., Ltd., 23-0711 (D. Del.) | 30-Jun-23 | Hon. Stephanos Bibas | Oracea® (doxycycline capsules | 7,749,532 8,206,740 |
| Intercept Pharms., Inc. v. Zenara Pharma Private Ltd., 23-0714 (D. Del.) | 30-Jun-23 | Hon. Maryellen Noreika | Ocaliva® (obeticholic acid tablets) | RE48,286 |
| Boehringer Ingelheim Pharms. Inc. v. Anobri Pharms. US, LLC, 23-0715 (D. Del.) | 30-Jun-23 | Hon. Gregory B. Williams | Spiriva® Respimat® (tiotropium bromide inhalation spray) | 7,284,474 7,896,264 7,396,341 9,027,967 7,837,235 8,733,341 |
| Boehringer Ingelheim Pharms. Inc. v. Anobri Pharms. US, LLC, 23-0716 (D. Del.) | 30-Jun-23 | Hon. Gregory B. Williams | Combivent® Respimat® (ipratropium bromide / albuterol inhalation spray) | 7,284,474 7,896,264 7,396,341 9,027,967 7,837,235 8,733,341 |
| Pfizer Inc. v. Aurobindo Pharma Ltd., 23-0717 (D. Del.) | 30-Jun-23 | Hon. Colm F. Connolly | Xeljanz® XR (tofacitinib citrate extended-release tablets) | RE41,783 |
| Pfizer Inc. v. Sun Pharm. Indus. Ltd., 23-0718 (D. Del.) | 30-Jun-23 | Hon. Colm F. Connolly | Xeljanz® XR (tofacitinib citrate extended-release tablets) | RE41,783 |
GENERICally Speaking Hatch Waxman Bulletin
GENERICally Speaking Hatch Waxman Bulletin
READ MORE Related Publications
First Quarter
GENERICally Speaking: A Hatch-Waxman Litigation Bulletin
Oren Langer, Christopher Pinahs, Emily Tremblay, and Christine May
March 25, 2024
Endo Ventures Unlimited Co. v. Nexus Pharms. Inc.
GENERICally Speaking Hatch Waxman Bulletin
March 22, 2024
Mallinckrodt plc v. Airgas Therapeutics LLC
GENERICally Speaking Hatch Waxman Bulletin
March 8, 2024
UCB, Inc. v. Mylan Techs. Inc.
GENERICally Speaking Hatch Waxman Bulletin
March 5, 2024
Genentech, Inc. v. Sandoz, Inc.
GENERICally Speaking Hatch Waxman Bulletin
Related News
October 14, 2022
September 9, 2022
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.